PMX-DHP-2h (n = 7) | PMX-DHP-12h (n = 16) | P value | |
---|---|---|---|
Age, year, median (IQR) | 75 (66–81) | 78 (60–84) | 0.92 |
Male, number (%) | 4 (57%) | 6 (38%) | 0.65 |
Body mass index, median (IQR) | 20.2 (18.8–22.2) | 22.3 (21.6–25.7) | 0.04 |
APACHE II score at ICU admission, median (IQR) | 21 (17–28) | 23 (18–31) | 0.64 |
SOFA score at the day of the first PMX-DHP session, median (IQR) | 11 (7–11) | 10 (8–14) | 0.84 |
Comorbidity | |||
Immunosuppression, number (%) | 2 (29%) | 4 (25%) | 1.00 |
Chronic dialysis, number (%) | 1 (14%) | 2 (13%) | 1.00 |
Home oxygenation therapy, number (%) | 0 (0%) | 1 (7%) | 1.00 |
Decompensate heart failure, number (%) | 1 (14%) | 1 (7%) | 0.53 |
Diabetes mellitus, number (%) | 0 (0%) | 3 (19%) | 0.53 |
Site of infection | 0.11 | ||
Abdomen, number (%) | 3 (43%) | 13 (81%) | |
Urinary tract, number (%) | 2 (29%) | 1 (6%) | |
Others, number (%)* | 2 (29%) | 2 (13%) | |
Causative organisms | 0.10 | ||
Gram-negative rod, number (%) | 2 (29%) | 1 (6%) | |
Mixed, number (%) | 1 (14%) | 7 (44%) | |
Gram-positive bacteria, number (%) | 2 (29%) | 3 (19%) | |
Fungi, number (%) | 0 (0%) | 1 (6%) | |
Unknown, number (%) | 2 (29%) | 4 (25%) | |
Number of PMX-DHP session | 1.00 | ||
1 session, number (%) | 3 (43%) | 6 (38%) | |
2 sessions, number (%) | 4 (57%) | 10 (62%) | |
Treatment in ICU | |||
Continuous renal replacement therapy, number (%) | 1 (15%) | 8 (50%) | 0.18 |
Mechanical ventilation, number (%) | 7 (100%) | 16 (100%) | 1.00 |
Low dose steroid, number (%) | 5 (71%) | 14 (87%) | 0.56 |
Laboratory test† | |||
White blood cell, 102/mcl, median (IQR) | 89 (14–121) | 88 (34–144) | 0.53 |
C reactive protein, mg/dl, median (IQR) | 9.1 (6.1–18.9) | 15.9 (8.0–24.4) | 0.15 |
Total bilirubin, mg/dl, median (IQR) | 0.9 (0.7–1.5) | 0.8 (0.5–2.0) | 0.81 |
Creatinine, mg/dl, median (IQR) | 1.8 (0.9–2.6) | 1.6 (1.2–2.5) | 0.76 |
PT-INR, median (IQR) | 1.3 (1.1–1.4) | 1.3 (1.2–1.7) | 0.71 |
Lactate, mmol/l, median (IQR) | 5.1 (1.4–8.5) | 3.8 (2.0–7.5) | 0.84 |